New glaucoma medications in the geriatric population: Efficacy and safety

Journal of the American Geriatrics Society

Volumn 50, Issue 5, 2002, Pages 956-962

  Novack, Gary D ^a   O'Donnell, Martin J ^b   Molloy, D William ^b  

^a PHARMALOGIC DEVELOPMENT INC   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Adverse events; Bimatoprost; Brimonidine; Brinzolamide; Dorzolamide; Geriatrics; Glaucoma; Latanoprost; Safety; Timolol; Travoprost

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHAGAN P; ANTIGLAUCOMA AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARBACHOL; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; PURITE; TIMOLOL; TIMOLOL MALEATE; TRAVOPROST; UNCLASSIFIED DRUG; UNOPROSTONE ISOPROPYL ESTER;

BRADYCARDIA; BRONCHOSPASM; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FOOD AND DRUG ADMINISTRATION; GERIATRIC DISORDER; GLAUCOMA; HEADACHE; HUMAN; HYPEREMIA; INTRAOCULAR PRESSURE; IRIS DISEASE; REVIEW; TASTE DISORDER; XEROSTOMIA;

ADRENERGIC AGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGED; CARBONIC ANHYDRASE INHIBITORS; GERIATRICS; GLAUCOMA; HUMANS; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS, SYNTHETIC;

EID: 0036247692     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1532-5415.2002.50226.x     Document Type: Review

References (64)

1. Age-specific causes of bilateral visual impairment
2. Prevalence of age-related maculopathy. The beaver dam eye study
3. The probability of blindness from open-angle glaucoma
4. Rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual field damage
5. Blindness incidence in Germany. A population-based study from Wurttemberg-Hohenzollern
6. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration
7. Diuretics
8. The pharmacology of methazolamide in relation to the treatment of glaucoma
9. Carbonic anhydrase: General perspectives and advances in glaucoma research
10. Monitoring patients taking oral carbonic anhydrase inhibitors
11. The respiratory function of the aqueous
12. Dorzolamide versus pilocarpine as adjunctive therapies to timolol: A comparison of patient preference and impact on daily life
13. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol
14. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide
15. Population pharmacokinetics of 2% topical dorzolamide in the aqueous humor of humans
16. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure
17. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes
18. Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt)
19. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension
20. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt©) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy
21. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting
22. The ocular comfort of t.i.d.-dosed brinzolamide 1% compared to t.i.d.-dosed dorzolamide 2% in patients with primary open-angle glaucoma or ocular hypertension
23. The brinzolamide comfort study group. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution. Results from two multicenter comfort studies
24. Treatment adherence
25. Self-medication with pilocarpine among outpatients in a glaucoma clinic
26. Compliance with topical pilocarpine treatment
27. Ophthalmic beta-blockers since timolol
28. Betaxolol in patients with glaucoma and asthma
29. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985
30. The toxicity of topical ophthalmic beta-blockers
31. Effect of clonidine on aqueous humor flow in normal human eyes
32. Die augendrucksenkende wirkung von pilokarpin und adrenalin-dipivalat bei glaucoma simplex. Eine kontrollierte klinische studie
33. Effect of apraclonidine in long-term timolol users
34. Clonidine, Effects of a topically administered solution on intraocular pressure and blood pressure in open-angle glaucoma
35. The effect of topical clonidine on intraocular pressure
36. The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers
37. Short-term effects of unilateral 1% apraclonidine therapy
38. A limited comparison of apraclonidine's dose response in subjects with normal or increased intraocular pressure
39. Hypotony following instillation of apraclonidine for increased intraocular pressure after trabeculoplasty
40. Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes
41. 2-adrenergic agonists in the medical treatment of glaucoma
42. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure
43. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial
44. Eicosanoids as a new class of ocular hypotensive agents. Comparison of the apparent mechanism of the ocular hypotensive effects of A and F type prostaglandins
45. Comparative phase III clinical trial of latanoprost and timolol in patients with elevated intraocular pressure
46. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients
47. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension
48. Phase III double masked comparative study of UF-021 ophthalmic solution in primary open-angle glaucoma and ocular hypertention
49. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension
50. A comparison of the intraocular pressure-lowering effect of 0.5% timolol maleate and the docosanoid derivative of a PGF(2alpha) metabolite, 0.12% unoprostone, in subjects with chronic open-angle glaucoma or ocular hypertension
51. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension
52. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics
53. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure
54. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension
55. Improving the therapeutic index of topically applied ocular drugs